Byondis Seeks Partner For Lead ADC To Enter Crowded Breast Cancer Market

Netherlands-based Byondis B.V.’s lead candidate product, the next-generation antibody-drug conjugate, SYD985, has met its primary endpoint in the Phase III TULIP study in HER2-positive advanced breast cancer, and the company intends to explore partnering for the product, which it expects to submit for regulatory approval by the end of 2021. 

Although Byondis’s novel ADC would offer patients a new treatment option, it would be entering an increasingly crowded market for such therapeutics for HER2-positive breast cancer. The Nijmegen, Netherlands-based biotech...